Ashenafi Bulle

4PUBLICATIONS
37CO-AUTHORS
Molecular targetsCancer cell biologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|Apr 20, 2026
Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities.

|Sep 23, 2020
Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer.

Namrata Khurana, Paarth B Dodhiawala, Ashenafi Bulle

|Aug 09, 2020
Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts.

Ashenafi Bulle, Jeroen Dekervel, Lise Deschuttere

Pageof 1

Frequent Collaborators

3 joint publications

Kian-Huat Lim

1 joint publications

Jeroen Dekervel

1 joint publications

David Nittner

1 joint publications

Jos van Pelt